(Also see "Questions Remain For Samsung Bioepis Post-Biogen" - Generics Bulletin, 8 February, 2022.)	In exclusive comments made to Generics Bulletin, Samsung Biologics has acknowledged that it has yet to decide on several aspects of Samsung Bioepis’ management, structure and strategic focus once Biogen completes the sale of its stake in the biosimilars joint venture to its partner.
(Also see "Synaffix Aims For Top ADC Tech Provider Spot After Inking MacroGenics Deal" - Scrip, 8 February, 2022.)	Synaffix's dream to become the number one antibody drug conjugate technology provider by 2023 has been bolstered by a flurry of recent strategic collaborations, including one with MacroGenics.
(Also see "Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar" - Generics Bulletin, 8 February, 2022.)	Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.
(Also see "Hiccup For Evotec As Bayer Pulls Plug On Chronic Cough Drug" - Scrip, 7 February, 2022.)	With the future of eliapixant in doubt, Shinogi's sivopixant struggling and a recent FDA rejection for Merck & Co's chronic cough drug gefapixant, Bellus Health's BLU-5937 looks to have emerged as a best-in-class agent in the P2X3 space.
(Also see "Alvotech In-Licenses Xolair Rival From BiosanaPharma" - Generics Bulletin, 2 February, 2022.)	Alvotech has delivered on indications that it would look to collaborate on certain biosimilar opportunities in future, striking a licensing deal with BiosanaPharma that will see the two firms partner to co-develop an omalizumab biosimilar rival to Xolair.
(Also see "A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers" - Scrip, 2 February, 2022.)	As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.
(Also see "Sio Gene Therapies’ Exit From Oxford Biomedica Parkinson’s Collaboration Leaves Hole In Commercial Prospects" - Scrip, 1 February, 2022.)	Sio Gene Therapies is returning its rights for a Parkinson’s disease program to Oxford Biomedica, leaving observers regretting the loss of a big market opportunity, while the US firms seeks a new CEO.
(Also see "Stada Expands Supply Network With Romanian Facility" - Generics Bulletin, 27 January, 2022.)	Stada is investing nearly €50m in a Romanian supply-chain hub that it says will support future growth for the company, benefiting from its central European location. Meanwhile, the company has also struck medical cannabis deals with German insurers AOK and IKK.
(Also see "J&J, Flush With Cash, Has Flexibility To Be ‘Bolder’ On M&A, CEO Duato Says" - Scrip, 25 January, 2022.)	Johnson & Johnson kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
(Also see "Evotec Adds To Spate Of Metabolic Deals With Lilly Collaboration" - Scrip, 18 January, 2022.)	Evotec inks its fifth metabolic disease collaboration as it teams up with US major Lilly to develop kidney disease and diabetes assets.
(Also see "UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy" - Scrip, 19 January, 2022.)	Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
(Also see "Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic" - Scrip, 19 January, 2022.)	Engitix has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.
(Also see "Hikma Buys Teligent Assets To Expand Into Canada" - Generics Bulletin, 17 January, 2022.)	Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.

Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation

More from Deal Watch

More from Deals